UCB: Oddo BHF raises TP
(CercleFinance.com) - Oddo BHF maintains its 'outperform' rating on UCB shares, with a target price raised from E168 to E180, following the announcement of positive top-line results for a Phase III study evaluating dapirolizumab pegol (DPZ) in lupus.
These headlines come as a really good surprise, as they could bring a new asset to the market in 2028 and thus improve the group's revenue diversification thereafter, the analyst points out.
Oddo BHF still believes that UCB has the capacity to achieve its 2025 guidance of an EBITDA margin of between 30% and 35%, and considers that it presents a strong growth profile (CAGR 2024-30 of 24%) and an attractive pipeline reward risk.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.
The information and analyses published by Cercle Finance are intended solely as a decision-making aid for investors. Cercle Finance cannot be held responsible, directly or indirectly, for the use of information and analyses by readers. Uninformed investors are advised to consult a professional advisor before investing. This information does not constitute an invitation to sell or a solicitation to buy.
These headlines come as a really good surprise, as they could bring a new asset to the market in 2028 and thus improve the group's revenue diversification thereafter, the analyst points out.
Oddo BHF still believes that UCB has the capacity to achieve its 2025 guidance of an EBITDA margin of between 30% and 35%, and considers that it presents a strong growth profile (CAGR 2024-30 of 24%) and an attractive pipeline reward risk.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.
The information and analyses published by Cercle Finance are intended solely as a decision-making aid for investors. Cercle Finance cannot be held responsible, directly or indirectly, for the use of information and analyses by readers. Uninformed investors are advised to consult a professional advisor before investing. This information does not constitute an invitation to sell or a solicitation to buy.